Nodal Response and Survival After Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive Breast Cancer: 20-Year Experience from a Single Institution.
Selena J AnChristine Hong Ngoc Che ThaiSherin IsmailChris B AgalaVan HoangTimothy FeeneyMargaret LillieAmy WhelessJulia M SelfridgeDavid W OllilaKristalyn K GallagherLisa A CareyPhilip M SpanheimerPublished in: Annals of surgical oncology (2024)
In HR+ BC treated with NET, long-term disease-free survival is good, although nodal pCR is uncommon for cN+ patients. Future studies are needed to elucidate optimal neoadjuvant systemic therapy and to delineate oncologically safe strategies to deescalate axillary management for residual microscopic disease.
Keyphrases
- lymph node
- free survival
- positive breast cancer
- neoadjuvant chemotherapy
- rectal cancer
- locally advanced
- newly diagnosed
- end stage renal disease
- ejection fraction
- sentinel lymph node
- lymph node metastasis
- peritoneal dialysis
- stem cells
- mesenchymal stem cells
- patient reported outcomes
- ultrasound guided
- early stage
- bone marrow
- case control